Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iruplinalkib as Postoperative Adjuvant Therapy in Stage IA ALK-positive NSCLC
NCT07330076Phase 2Not yet recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Jan 2026
- Primary completion
- Dec 2030
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of iruplinalkib in non-small cell lung cancer (NSCLC), sponsored by Tianjin Medical University Cancer Institute and Hospital. Primary endpoint: Disease-Free Survival at 3 years. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
iruplinalkib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07330076.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07330076.